• Decitabine Priming Enhances Anti–PD-1 Responses

  2026-08-28

  The reference study shows that low-dose Decitabine, or 5-Aza-2'-deoxycytidine, can improve anti–PD-1 efficacy by expanding and preserving CD8+ progenitor exhausted T cells rather than simply increasing nonspecific cytotoxicity. Its mechanistic contribution is the identification of sustained JunD and JNK/AP-1 activity as part of the T-cell response associated with improved tumor control.

• NSC-23766 for Rac1 Pathway Assay Design

  2026-08-28

  Use NSC-23766 as a context-aware Rac GTPase inhibitor to connect Rac1 activation with cancer phenotypes, endothelial barrier changes, and insulin-independent glucose transport. This workflow emphasizes dose planning, orthogonal readouts, formulation control, and troubleshooting rather than treating one IC50 as universally predictive.

• Phenothiazines Activate Macrophage Antibacterial Defenses

  2026-08-27

  A 2025 Frontiers in Immunology study shows that phenothiazines, including Perphenazine, strengthen macrophage control of intracellular bacteria through coordinated ROS accumulation, lysosomal activation, and autophagy. The work supports a host-directed antibacterial strategy and provides a mechanistic framework for testing phenothiazine compounds without assuming that their established dopamine pharmacology explains the immune phenotype.

• Angiotensin 1/2 (5-7): From RAS to Translation

  2026-08-27

  A mechanistic and translational perspective on Angiotensin 1/2 (5-7), connecting renin-angiotensin system biology, hypertension research, assay design, and emerging SARS-CoV-2 receptor-binding evidence.

• Bay 11-7085: From NF-κB Blockade to Causal Insight

  2026-08-26

  Bay 11-7085 is an NF-κB activation inhibitor that helps separate pathway engagement from downstream inflammation, cell-cycle arrest, and apoptosis. This guide interprets its use alongside ER stress-linked neuroinflammation research and outlines decision-focused assay strategies, controls, and limitations.

• ECL Chemiluminescent Substrate Kit for TNBC

  2026-08-26

  Learn how the ECL Chemiluminescent Substrate Detection Kit supports rigorous immunoblotting of the Lin28B/Let-7/PBK pathway in triple-negative breast cancer research, with practical guidance for sensitivity, dynamic range, and mechanistic validation.

• Cyanine 3 Tyramide for Reliable Cell Assays

  2026-08-25

  Learn how Cyanine 3 Tyramide (SKU K1085) can improve low-abundance fluorescence detection in immunohistochemistry, in situ hybridization, and selected cell-based workflows. This scenario-driven guide distinguishes signal amplification from direct viability measurement and provides practical recommendations for reconstitution, controls, storage, and data interpretation.

• From mRNA Fate to Function in Translational Research

  2026-08-25

  Translational mRNA research succeeds when delivery, intracellular localization, innate sensing, and protein production are measured as connected events. This article explains how ARCA Cy5 EGFP mRNA (5-moUTP) can help researchers distinguish cellular uptake from productive translation and build more decision-ready mRNA delivery workflows.

• Rucaparib Workflows for DNA Damage Research

  2026-08-24

  Rucaparib (AG-014699) provides a practical way to interrogate PARP1-dependent DNA repair, radiosensitization, and persistent damage signaling in cancer models. This guide connects reagent handling with reproducible cell-based assays and shows how to separate transcriptional loss from cell death when interpreting results.

• Gastrodin, AT1 Signaling, and Reactive Astrocytes

  2026-08-23

  A 2024 European Journal of Neuroscience study shows that inflammatory microglia-conditioned medium reshapes the renin–angiotensin system, SIRT3, and reactive astrocyte markers in TNC-1 cells. Gastrodin counteracted several of these changes, while AT1 inhibition with Azilsartan supported a role for AT1 signaling in regulating astrocyte responses.

• TSPAN18–STIM1 Signaling in Prostate Cancer Bone Metastasis

  2026-08-22

  Zhou et al. identify TSPAN18 as a previously unrecognized regulator of STIM1 stability in prostate cancer, showing that it blocks TRIM32-mediated ubiquitination and sustains store-operated calcium entry. The study connects this protein-quality-control mechanism with tumor-cell motility, bone metastasis, and adverse clinical features, while providing a framework for testing the STIM1–Ca2+ axis in prostate cancer research.

• Protoporphyrin IX in Ferroptosis and Photodynamic Assays

  2026-08-21

  Protoporphyrin IX connects heme biology, iron handling, and light-triggered oxidative assays, but its insolubility makes formulation and controls decisive. This practical guide translates the METTL16-SENP3-LTF ferroptosis study into assay choices without overstating evidence for Protoporphyrin IX as an HCC treatment.

• Sulfisomidine Research Workflows

  2026-08-20

  Sulfisomidine, also known as sulfamethin, connects antibacterial metabolism studies with hPON1 enzyme inhibition and environmental transformation research. This practical guide covers assay setup, concentration planning, historical pharmacokinetic insights, and troubleshooting for reproducible in vitro workflows.

• Tacalcitol monohydrate: Assay Design Guide

  2026-08-20

  This scenario-based guide explains how Tacalcitol monohydrate, SKU C8714, can be integrated into keratinocyte, viability, proliferation, and colorectal cancer workflows. It connects concentration selection, solvent control, storage, NGF induction, and 5-fluorouracil combination studies to published and product-specific evidence.

• EZ Cap Cy5 Firefly Luciferase mRNA Workflow

  2026-08-19

  Build a quantitative mRNA delivery workflow that separates cellular uptake from productive translation. EZ Cap Cy5 Firefly Luciferase mRNA combines direct Cy5 tracking with luciferase-based expression measurement, making it useful for screening LNP formulations, optimizing transfection, and comparing intracellular trafficking.

445 records 6/30 page Previous Next First page 上5页 678910 下5页 Last page